The rise and fall of gabapentin for bipolar disorder: A case study on off-label pharmaceutical diffusion

Medical Care

Volumn 48, Issue 4, 2010, Pages 372-379

  Fullerton, Catherine A ^a,b   Busch, Alisa B ^a,c   Frank, Richard G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Psychiatry Cambridge Health Alliance ^*  (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Bipolar disorder; Gabapentin; Information dissemination; Off label use; Prior authorization policy

Indexed keywords

GABAPENTIN;

ADULT; ARTICLE; BIPOLAR DISORDER; DRUG MARKETING; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE POLICY; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; TREND STUDY; UNITED STATES;

ADOLESCENT; ADULT; AMINES; ANTI-ANXIETY AGENTS; BIPOLAR DISORDER; CYCLOHEXANECARBOXYLIC ACIDS; EVIDENCE-BASED MEDICINE; FEMALE; FLORIDA; GAMMA-AMINOBUTYRIC ACID; HUMANS; INFORMATION DISSEMINATION; LOGISTIC MODELS; MALE; MARKETING OF HEALTH SERVICES; MEDICAID; MIDDLE AGED; OBSERVATION; OFF-LABEL USE; UNITED STATES; YOUNG ADULT;

EID: 77950202877     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181ca404e     Document Type: Article

References (56)

1. Kaiser Family Foundation. Prescription Drug Trends [5]. 2007. Available at: http://www.kff.org/rxdrugs/upload/3057-06.pdf.
2. Centers for Medicare and Medicaid Services. National Health Expenditure Accounts, Historical. Available at: http://www.cms.hhs. gov/ NationalHealthExpendData/. Accessed July 25, 2008.
3. Geroski PA Models of technology diffusion. Res Policy. 2000;29:603-625.
4. Druss BG, Marcus SC, Olfson M, et al. Listening to generic prozac: winners, losers, and sideliners. Health Aff (Millwood). 2004;23:210-216.
5. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27:w185-w195.
6. Delate T, Mager DE, Sheth J, et al. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am JManag Care. 2005;11:29-36.
7. Fischer MA, Cheng H, Schneeweiss S, et al. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Med Care. 2006;44:658-663.
8. Siracuse MV, Vuchetich PJ. Impact of medicaid prior authorization requirement for COX-2 Inhibitor drugs in Nebraska. Health Serv Res. 2008;43:435-450.
9. Smalley WE, Griffin MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;332:1612-1617.
10. Steinman M, Bero LA, Chren M-M, et al. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284-293.
11. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiol Drug Saf. 2005;14:629-638.
12. Hamer AM, Haxby DG, McFarland BH, et al. Gabapentin use in a managed Medicaid population. J Manag Care Pharm. 2002;8:266-271.
13. Radley DC, Finkelstein SN, Stafford R. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021-1026.
14. Florida Medicaid. Medicaid Prescribed Drug Spending Control Program Initiatives: Quarterly Report, July 1-September 30, 2004. Available at: http://www.fdhc.state.fl.us/Medicaid/Prescribed-Drug/pdf/quarterly-report- 09-30-04.pdf. Accessed March 5, 2008.
15. Agency for Health Care Administration. Medicaid Services. Historical Remittance Banner Messages. Available at: http://www.fdhc.state.fl.us/ Medicaid/Prescribed-Drug/banner-history.shtml. Accessed March 5, 2008.
16. Serpell MG; Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-566.
17. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpectic neuralgia: a randomized controlled trial. JAMA. 1998; 280:1837-1842.
18. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931-1937.
19. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9:559-568.
20. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Bipolar Dis-ord. 2000;2:249-255.
21. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607-614.
22. Centers for Medicare and Medicaid Services, Office of Research Development and Information, Mathematica Policy Research. The Medicaid Analytic Extract Chartbook 2007. Available at: http://www.cms.hhs.gov/ MedicaidDataSourcesGenInfo/Downloads/MAX-Chartbook-2007. pdf. Accessed September 28 2007.
23. Nemeroff CB, Kaladi A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64:466-472.
24. Unutzer J, Simon G, Pabiniak C, et al. The treated prevalence of bipolar disorder in a large staff-model HMO. Psychiatr Serv. 1998;49:1072-1078.
25. Unutzer J, Simon G, Pabiniak C, et al. The use of administrative data to assess quality of care for bipolar disorder in a large staff model HMO. Gen Hosp Psychiatry. 2000;22:1-10.
26. Busch AB, Huskamp HA, Landrum MB. Bipolar-I disorder in a Med-icaid population: Correlates of quality of care. Psychiatr Serv. 2007;58: 848-854.
27. Busch AB, Huskamp HA, Neelon B, et al. Longitudinal racial/ethnic disparities in antimanic medication use in bipolar-I disorder. Med Care. 2009;47:1217-1228.
28. Busch AB, Ling DC, Frank RG, et al. Changes in bipolar-I disorder quality of care during the 1990's. Psychiatr Serv. 2007;58:27-33.
29. Busch AB, Frank RG, Lehman AF, et al. Co-occurring substance use disorders and quality of care: the differential effect of a managed behavioral health care carve-out. Adm Policy Ment Health. 2006;33: 388-397.
30. Busch AB, Frank RG, Lehman AL. The effect of a managed behavioral health care carve-out on quality of care for Medicaid patients diagnosed with schizophrenia. Arch Gen Psychiatry. 2004;61:442-448.
31. Busch AB, Huskamp HA, Normand SL, et al. The impact of parity on major depression treatment quality on the federal employees' health benefits program after parity implementation. Med Care. 2006;44:506-512.
32. Busch AB, Lehman AF, Goldman HH, et al. Changes over time and disparities in schizophrenia treatment quality. Med Care. 2009;44:199-207.
33. Frank RG, Berndt ER, Busch AB, et al. Quality constant "prices" for the ognoing treatment of schizophrenia: an exploratory study. Q Rev Econ Finance. 2004;44:390-409.
34. Ellis ER, Smith VK, Rousseau DM. Medicaid Enrollment in 50 States: June 2004 Data Update. Washington, DC: The Kaiser Commission on Medicaid and the Uninsured; 2005.
35. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
36. Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics. 2005;5:785-822.
37. Steinman M, Harper GM, Chren MM, et al. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007;4:e134.
38. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry. 1991;48:915-921.
39. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of balproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992;149:108-111.
40. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press, Inc; 1990.
41. Weiss RD, Greenfield SF, Najavits LM, et al. Medication compliance among patients with bipolar and substance use disorder. J Clin Psychiatry. 1998;59:172-174.
42. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63:384-390.
43. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159: 1-50.
44. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841-849.
45. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999;60:79-88.
46. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005; 187:229-234.
47. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66: 111-121.
48. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164:884-891.
49. Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009;66:633-639.
50. Grol R, Grimshaw J. From best evidence to best practice; effective implementation of change in patient's care. Lancet. 2003;362:1225-1230.
51. Weiss AP. Measuring the impact of medical research: moving from outputs to outcomes. Am J Psychiatry. 2007;164:206-214.
52. Oxman AD, Thomson MA, Davis DA, et al. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ. 1995;153:1423-1431.
53. Shaneyfelt M. Building bridges to quality. JAMA. 2001;286:2600-2601.
54. Bauer M. A review of quantitative studies of adherence to mental health clinical practice guidelines. Harv Rev Psychiatry. 2002;10:138-153.
55. Soumerai SB. Benefits and risks of increasing restriction on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23:135-146.
56. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.